Recent results have shown that also CD11b+ conventional DCs can present tumor-derived antigens on MHC class I molecules upon interferon stimulation and thus contribute to anti-tumor CD8+ T cell immunity [20]. This evidence concerns the gene ITGAM and neoplasm.